Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $42.4 million.

  • Lineage Cell Therapeutics' Goodwill & Intangibles fell 4483.89% to $42.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year decrease of 4483.89%. This contributed to the annual value of $57.2 million for FY2024, which is 3.84% down from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Goodwill & Intangibles is $42.4 million, which was down 4483.89% from $42.4 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Goodwill & Intangibles peaked at $76.8 million during Q1 2021, and registered a low of $42.4 million during Q2 2025.
  • Moreover, its 5-year median value for Goodwill & Intangibles was $57.2 million (2024), whereas its average is $62.9 million.
  • Its Goodwill & Intangibles has fluctuated over the past 5 years, first soared by 3435.77% in 2023, then tumbled by 4483.89% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Goodwill & Intangibles (Quarter) stood at $76.8 million in 2021, then changed by 0.0% to $76.8 million in 2022, then dropped by 25.49% to $57.2 million in 2023, then dropped by 0.04% to $57.2 million in 2024, then fell by 25.94% to $42.4 million in 2025.
  • Its last three reported values are $42.4 million in Q3 2025, $42.4 million for Q2 2025, and $57.2 million during Q1 2025.